搜索：ADC
-
A Highly Differentiated B7-H3 x PSMA Bispecific ADC, Potentially Best-in-Class, for the Treatment of mCRPC 【Product for Licensing】
If you are interested in this candidate, please contact DrugTimes BD Team at BD@drugtimes.cn
-
默沙东“首款” ADC III期研究结果公布，两名患者死亡！
美东时间2024年9月17日，默沙东/第一三共宣布，其共同开发/商业化的 First In Class ADC药物——HER3-DXD（ patritumab deruxtecan…
-
尿路上皮癌治疗进入ADC时代！首个Nectin-4 ADC国内获批后，一线治疗也不远了
2024年8月23日，一场关于尿路上皮癌的疾病科普及治疗进展沟通会在上海举办。 会议上，复旦大学附属肿瘤医院泌尿外科主任医师叶定伟教授就尿路上皮癌的发病特点、高危因素、预防手段以及…
-
当ADC叩响 “痴呆症” 的大门
2024年7月28日-8月1日，阿尔茨海默病协会国际会议（AAIC）在费城成功举办。会议上，来自世界各地的专业研究人员和临床医生就阿尔茨海默病（AD）的防治分享了各自精彩见解。 在…
-
美国上市公司寻找创新性ADC、双抗，您感兴趣吗？| 药时代BD项目
如果贵公司对这个机会感兴趣，请速速联系药时代BD团队！
-
American listed companies are looking for innovative ADCs and bispecific antibodies. Are you interested in this opportunity? | DrugTimes BD Project
Please contact the DrugTimes BD team as soon as possible!
-
诺和、礼来看好的ADC payload，您感兴趣吗？| 药时代BD项目
如果贵公司对新型NMTi payload感兴趣，请速速联系药时代BD团队！
-
Novo and Eli Lilly’s favored ADC payload, are you interested? | DrugTimes BD Project
If your company is interested in the new NMTi payload, please contact DrugTimes BD team as soon as possible!
-
Gilead | A Ray of Hope for the Highly Anticipated TROP2 ADC Trodelvy
DrugTimes team will follow up on this hot field and report timely. Please stay tuned. Many thanks!~
-
ANTI-CDCP1 mAb and ADC 【Product for Licensing】
If interested, please contact DrugTimes BD Team at BD@drugtimes.cn. We will discuss with you and may present the non-confidential deck to you for review asap.
